CoChat
Sign Up
Cited by 57Lung Cancer Research StudiesAdvanced Glycation End Products researchFerroptosis and cancer prognosis

The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer

Open access
Feng, Anlin, Tu, Zhenbo, Yin, Bingjiao·2016·Oncotarget
DOI 10.18632/oncotarget.7050PMC PMC4991471
Open this paper in CoChat — free accountOpen PDF

Abstract

// Anlin Feng 1, * , Zhenbo Tu 2, * , Bingjiao Yin 1 1 Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China, 430030 2 Department of Immunology, Wuhan University School of Basic Medical Sciences, Wuhan, Hubei, People’s Republic of China, 430071 * These authors have contributed equally to this work Correspondence to: Bingjiao Yin, e-mail: ybjzm79@yeah.net Keywords: HMGB1, NSCLC, biomarker, prognosis, ADC Received: September 30, 2015 Accepted: January 20, 2016 Published: January 28, 2016 ABSTRACT Several studies have assessed the diagnostic and prognostic values of high mobility group protein box 1 (HMGB1) expression in non-small cell lung cancer (NSCLC), but these results remain controversial. The purpose of this study was to perform a meta-analysis of the gene microarray analyses of datasets from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) to evaluate the association of HMGB1 expression with the clinicopathological and prognostic features of patients with NSCLC. Furthermore, we investigated the underlying molecular mechanisms by bioinformatics analysis. Twenty relevant articles involving 2651 patients were included in this meta-analysis; the HMGB1 expression in NSCLC tissues was significantly higher than that in the healthy non-cancer control tissues. We also found an indication by microarray analysis and meta-analysis that HMGB1 expression was associated with the cancer TNM Staging System. In terms of prognostic features, a survival analysis from KM-Plotter tool revealed that the high HMGB1 expression group exhibited poorer survival in lung adenocarcinoma (ADC) and overall NSCLC patients. The survival and disease-free analyses from TCGA datasets also showed that HMGB1 mainly affected the development of patients with ADC. Therefore, we focused on how HMGB1 affected the prognosis and development of ADC using bioinformatics analyses and detected that the mitogen-activated protein kinases (MAPK), apoptosis and cell cycle signaling pathways were the key pathways that varied during HMGB1 up-regulation in ADC. Moreover, various genes such as PLCG2, the phosphatidylinositol-4, 5-bisphosphate 3-kinase superfamily (PI3Ks), protein kinase C (PKC) and DGKZ were selected as hub genes in the gene regulatory network. Our results indicated that HMGB1 is a potential biomarker to predict progression and survival of NSCLC, especially of ADC types.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.7050

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PLCγ2 associated with the EGFR pathway was a risk factor in non-small-cell lung cancer associated with HMGB1 expression.

    “Population studies and microarray analyses also revealed PLCγ2 associated with the EGFR pathway was a risk factor in esophageal squamous cell carcinoma and gastric cancer (149), in non–small-cell lung cancer associated with HMGB1 expression (150), and as upregulated and potentially involved in triple-negative breast cancer–associated BRAC1 in a Chinese patient cohort (151).”

    From The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration (2021) · cites this paper as [150]

    The Results section (‘The molecular mechanisms of HMGB1 in NSCLC’; page unavailable) identifies PLCG2 as a central gene in a network analyzed alongside HMGB1 in lung adenocarcinoma. It does not identify PLCG2 as an NSCLC risk factor or establish its association with the EGFR pathway; the reported prognostic association concerns HMGB1 expression, not PLCG2. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 52

  1. [1]Lotze MT Tracey KJ High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal Nat Rev Immunol 2005 5 331 342 15803152
  2. [2]Thomas JO Stott K H1 and HMGB1: modulators of chromatin structure Biochem Soc Trans 2012 40 341 346 22435809
  3. [3]Bustin M Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins Mol Cell Biol 1999 19 5237 5246 10409715 PMC84367
  4. [4]Stros M Muselikova-Polanska E Pospisilova S Strauss F High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops Biochemistry 2004 43 7215 7225 15170359
  5. [6]Gebhardt C Riehl A Durchdewald M Nemeth J Furstenberger G Muller-Decker K Enk A Arnold B Bierhaus A Nawroth PP Hess J Angel P RAGE signaling sustains inflammation and promotes tumor development J Exp Med 2008 205 275 285 18208974 PMC2271015
  6. [7]Mittal D Saccheri F Venereau E Pusterla T Bianchi ME Rescigno M TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells EMBO J 2010 29 2242 2252 20526283 PMC2905255
  7. [8]Suren D Yildirim M Demirpence O Kaya V Alikanoglu AS Bulbuller N Yildiz M Sezer C The role of high mobility group box 1 (HMGB1) in colorectal cancer Med Sci Monit 2014 20 530 537 24681824 PMC3976146
  8. [9]Choi YR Kim H Kang HJ Kim NG Kim JJ Park KS Paik YK Kim HO Kim H Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation Cancer Res 2003 63 2188 2193 12727838
  9. [10]Hao Q Du XQ Fu X Tian J Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma [Article in Chinese] Zhonghua Zhong Liu Za Zhi 2008 30 292 295 18788635
  10. [11]Li Y Tian J Fu X Chen Y Zhang W Yao H Hao Q Serum high mobility group box protein 1 as aclinical marker for ovarian cancer Neoplasma 2014 61 579 584 25030441
  11. [12]Yan W Chang Y Liang X Cardinal JS Huang H Thorne SH Monga SP Geller DA Lotze MT Tsung A High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases Hepatology 2012 55 1863 1875 22234969 PMC4610360
  12. [13]Song B Song WG Li ZJ Xu ZF Wang XW Wang CX Liu J Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells Cell biochemistry and function 2012 30 11 17 21953494
  13. [14]Mitola S Belleri M Urbinati C Coltrini D Sparatore B Pedrazzi M Melloni E Presta M Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine J Immunol 2006 176 12 15 16365390
  14. [15]Tang D Kang R Livesey KM Kroemer G Billiar TR Van Houten B Zeh HJ 3rd Lotze MT High-mobility group box 1 is essential for mitochondrial quality control Cell Metab 2011 13 701 711 21641551 PMC3293110
  15. [16]Kang R Tang D Schapiro NE Loux T Livesey KM Billiar TR Wang H Van Houten B Lotze MT Zeh HJ The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics Oncogene 2014 33 567 577 23318458 PMC3795800
  16. [17]DeSantis CE Lin CC Mariotto AB Siegel RL Stein KD Kramer JL Alteri R Robbins AS Jemal A Cancer treatment and survivorship statistics, 2014 CA Cancer J Clin 2014 64 252 271 24890451
  17. [18]Arima C Kajino T Tamada Y Imoto S Shimada Y Nakatochi M Suzuki M Isomura H Yatabe Y Yamaguchi T Yanagisawa K Miyano S Takahashi T Lung adenocarcinoma subtypes definable by lung development-related miRNA expression profiles in association with clinicopathologic features Carcinogenesis 2014 35 2224 2231 24903339
  18. [20]He DP Clinical pathological study of HMGB1 and β-catenin expression in non-small cell lung cancer Journal of Hainan Medical University 2014 20
  19. [21]He JJ Zhang CL Expression of HMGB1 and lung and their clinical sighificance Journal of Yanan University(Medical Sciences) 2012 10 1 10
  20. [22]Hou J Aerts J den Hamer B van Ijcken W den Bakker M Riegman P van der Leest C van der Spek P Foekens JA Hoogsteden HC Grosveld F Philipsen S Gene expression-based classification of non-small cell lung carcinomas and survival prediction PLoS One 2010 5 e10312 20421987 PMC2858668
  21. [23]Karlsson A Jonsson M Lauss M Brunnstrom H Jonsson P Borg A Jonsson G Ringner M Planck M Staaf J Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome Clin Cancer Res 2014 20 6127 6140 25278450
  22. [24]Lo FY Chang JW Chang IS Chen YJ Hsu HS Huang SF Tsai FY Jiang SS Kanteti R Nandi S Salgia R Wang YC The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization BMC Cancer 2012 12 235 22691236 PMC3488578
  23. [25]Naumnik W Nilklinska W Ossolinska M Chyczewska E Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy Folia Histochem Cytobiol 2009 47 703 709 20430742
  24. [26]Rousseaux S Debernardi A Jacquiau B Vitte AL Vesin A Nagy-Mignotte H Moro-Sibilot D Brichon PY Lantuejoul S Hainaut P Laffaire J de Reynies A Beer DG Timsit JF Brambilla C Brambilla E Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers Sci Transl Med 2013 5 186ra166 PMC4818008 23698379
  25. [27]Shang GH Jia CQ Tian H Xiao W Li Y Wang AH Dong L Lin DJ Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer Respir Med 2009 103 1949 1953 19535236
  26. [28]Shen X Hong L Sun H Shi M Song Y The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer Oncol Rep 2009 22 535 539 19639200
  27. [29]Su WM Bi MH The expression of HMGB1/MMP9 and its clinical significance in Non-Small Cell Lung Cancer Journal of Clinical Pulmonary Medicine 2012 17 1463 1465
  28. [31]Wang JY Expression and Significance of HMGB1, MMP9 and CEA in non-small cell lung cancer Dissertation for Doctor Degree (Shandong University) 2014
  29. [32]Wang Y Chen F Wang LZ Liu QF Yan WS Lin GH Liu J Li B Jiang XY Wang J Expression and significance of serum high mobility group box protein 1 in non - small cell lung cancer Journal of Modern Oncology 2014 22 1834 1836
  30. [33]Xu SB Mei XD The expression and clinical significance of HMGB1 and VEGF-C in lung cancer Shangdong Medical Journal 2009 49 50 51
  31. [34]Yang XM Yang H Expression of high mobility group box-1 in the lung tissue and serum of patients with pulmonary tuberculosis. [Article in Chinese] Zhonghua Jie He He Hu Xi Za Zhi 2013 36 497 500 24262084
  32. [35]Zhang SD Xu ML Expression and significance of HMGB1 and NF-κB p65 in non-small cell lung cancer Shangdong Medical Journal 2011 51
  33. [36]Zhang X Wang H Wang J Expression of HMGB1 and NF-kappaB p65 and its significance in non-small cell lung cancer Contemp Oncol (Pozn) 2013 17 350 355 24592122 PMC3934056
  34. [37]Gyorffy B Surowiak P Budczies J Lanczky A Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer PLoS One 2013 8 e82241 24367507 PMC3867325
  35. [38]Cerami E Gao J Dogrusoz U Gross BE Sumer SO Aksoy BA Jacobsen A Byrne CJ Heuer ML Larsson E The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer discovery 2012 2 401 404 22588877 PMC3956037
  36. [39]Gao J Aksoy BA Dogrusoz U Dresdner G Gross B Sumer SO Sun Y Jacobsen A Sinha R Larsson E Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Science signaling 2013 6 pl1 pl1 23550210 PMC4160307
  37. [40]Sun S Zhang W Cui Z Chen Q Xie P Zhou C Liu B Peng X Zhang Y High mobility group box-1 and its clinical value in breast cancer Onco Targets Ther 2015 8 413 419 25709474 PMC4334343
  38. [41]Zhang J Zhang R Lu WW Zhu JS Xia LQ Lu YM Chen NW Clinical significance of hmgb1 expression in human gastric cancer Int J Immunopathol Pharmacol 2014 27 543 551 25572734
  39. [42]Zhang L Han J Wu H Liang X Zhang J Li J Xie L Xie Y Sheng X Yu J The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review PLoS One 2014 9 e110626 25356587 PMC4214718
  40. [43]Sun KK Ji C Li X Zhang L Deng J Zhong N Wu XY Overexpression of high mobility group protein B1 correlates with the proliferation and metastasis of lung adenocarcinoma cells Mol Med Rep 2013 7 1678 1682 23467607
  41. [44]Liu PL Tsai JR Hwang JJ Chou SH Cheng YJ Lin FY Chen YL Hung CY Chen WC Chen YH Chong IW High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness Am J Respir Cell Mol Biol 2010 43 530 538 19933377
  42. [45]Chang YH Chen CM Chen HY Yang PC Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma Sci Rep 2015 5 10979 26042604 PMC4455286
  43. [46]De Mori R Straino S Di Carlo A Mangoni A Pompilio G Palumbo R Bianchi ME Capogrossi MC Germani A Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration Arterioscler Thromb Vasc Biol 2007 27 2377 2383 17872450
  44. [47]Saxena N Lahiri SS Hambarde S Tripathi RP RAS: target for cancer therapy Cancer Invest 2008 26 948 955 18798058
  45. [48]Downward J Targeting RAS signalling pathways in cancer therapy Nat Rev Cancer 2003 3 11 22 12509763
  46. [49]Kahl CR Means AR Regulation of cell cycle progression by calcium/calmodulin-dependent pathways Endocr Rev 2003 24 719 736 14671000
  47. [50]Colomer J Means AR Physiological roles of the Ca2+/CaM-dependent protein kinase cascade in health and disease Subcell Biochem 2007 45 169 214 18193638
  48. [51]Ueda Y Hirai S Osada S Suzuki A Mizuno K Ohno S Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf J Biol Chem 1996 271 23512 23519 8798560
  49. [52]Travis WD Pathology of lung cancer Clin Chest Med 2011 32 669 692 22054879
  50. [53]Devarakonda S Morgensztern D Govindan R Genomic alterations in lung adenocarcinoma Lancet Oncol 2015 16 e342 351 26149886
  51. [54]Comprehensive genomic characterization of squamous cell lung cancers Nature 2012 489 519 525 22960745 PMC3466113
  52. [55]Comprehensive molecular profiling of lung adenocarcinoma Nature 2014 511 543 550 25079552 PMC4231481

Cited by

Sorted by citations

Authors
Feng, A., Tu, Z., & Yin, B.
Affiliations
  • Huazhong University of Science and Technology (CN)
  • Wuhan University (CN)
Corresponding author
  • Feng, Anlin
  • Tu, Zhenbo
ORCID
Tu, Zhenbo
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2016-01-28
Volume
7
Issue
15
Pages
20507-20519
ISSN
1949-2553 (ISSN-L)
DOI
10.18632/oncotarget.7050
PMC
PMC4991471
OpenAlex
W2291589642
Cited by
57
References
1
Citations by year
2026: 2 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 7 · 2018: 23 · 2017: 8 · 2016: 1
FWCI
7.01
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Oncotarget (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
Keywords
HMGB1, non-small cell lung cancer, lung adenocarcinoma, prognostic factors, clinicopathological features, TNM staging, patient survival, MAPK signaling, apoptosis, cell cycle signaling, PLCγ2, PI3K/Akt signaling, gene expression signatures
MeSH terms
Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Prognosis, Biomarkers, Tumor, Meta-Analysis as Topic, Gene Expression Regulation, Neoplastic, Survival Rate, Case-Control Studies, HMGB1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review